First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to investigate the safety,
tolerability, pharmacokinetic (the effect of the body on the investigated drug),
pharmacodynamic biomarkers (biomarkers related to anti-IL-21 expected mode of action) and
signs of clinical efficacy of increasing single doses, at 9 i.v. (into the vein) dose levels
in Healthy Subjects , at 3 i.v. dose levels in subjects with rheumatoid arthritis (RA) and at
3 s.c. dose levels in Healthy Subjects.